VBI Vaccines

VBI Vaccines Inc. is a biopharmaceutical company focused on developing innovative vaccines for infectious diseases and immuno-oncology, operating in Israel, the United States, and internationally. The company's flagship product, Sci-B-Vac, is a prophylactic hepatitis B vaccine suitable for various age groups, including adults, children, and newborns. Utilizing its enveloped virus-like particle (eVLP) platform technology, VBI develops vaccines that closely mimic target viruses to provoke a strong immune response. Key candidates in its pipeline include VBI-1901, an immunotherapeutic vaccine for glioblastoma currently in Phase I/IIa clinical trials, and VBI-1501, a prophylactic cytomegalovirus vaccine that has completed Phase I trials. VBI collaborates with organizations like Brii Biosciences and GlaxoSmithKline, and has partnerships for developing a pan-coronavirus vaccine candidate and for the commercialization of its hepatitis B vaccine. Headquartered in Cambridge, Massachusetts, VBI Vaccines aims to address significant healthcare needs through its advanced vaccine technologies.